HIV/AIDS
Studies from Chelsea and Westminster Hospital NHS Trust yield new information about HIV/AIDS
Published in AIDS Weekly, September 14th, 2009
"Long-term antiretroviral therapy dramatically reduces H I V-related morbidity and mortality but is also associated with metabolic and morphological changes and requires high levels of adherence. A randomized, 48-week, open-label, comparative study of continuation of twice-daily zidovudine/lamivudine or replacement with once-daily tenofovir disoproxil fumarate/emtricitabine in individuals on successful efavirenz-based antiretroviral therapy," researchers in London, the United Kingdom report.
"Limb fat mass was assessed by dual x-ray absorptiometry in a subset of participants through week 48. Two hundred thirty-four individuals were randomized and treated (117 each to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2009-09-14)
More Articles from AIDS Weekly
- BioMed Central
Urine LAM-ELISA poor at diagnosing TB - Johns Hopkins Medical Institutions
HIV subtype linked to increased likelihood for dementia - University of Washington
Counting duplicated genome segments now possible - Biotechnology Business
Reports outline biotechnology business study results from Amgen, Inc. - Chlamydia
Research on chlamydia discussed by M.J. Mimiaga and co-researchers - Cytomegalovirus
Data on cytomegalovirus discussed by R. Richter and colleagues - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
